Intravenous immunoglobulin for resistant Clostridium difficile infection | Zendy

C. Murphy | Zendy; Martin Ver | Zendy; M. Cullen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Intravenous immunoglobulin for resistant Clostridium difficile infection

Author(s) -

C. Murphy,

Martin Ver,

M. Cullen

Publication year - 2005

Publication title -

age and ageing

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.014

H-Index - 143

eISSN - 1468-2834

pISSN - 0002-0729

DOI - 10.1093/ageing/afi212

Subject(s) - medicine , clostridium difficile , metronidazole , cholestyramine , clostridium difficile toxin a , antibiotics , vancomycin , rifampicin , antibody , enterocolitis , colitis , immune system , immunology , diarrhea , immunoglobulin a , clostridium difficile toxin b , microbiology and biotechnology , immunoglobulin g , bacteria , staphylococcus aureus , genetics , cholesterol , biology

Clostridium difficile (CD)-associated diarrhoea and colitis may relapse in up to 20% of treated patients. We present a patient who failed to respond over a 6-month period to treatment either singly or in combination with metronidazole, vancomycin, rifampicin, cholestyramine and probiotics. Her diarrhoea rapidly resolved after a 3-day course of intravenous immunoglobulin. This treatment may compensate for a failed immune response to CD toxin and should be considered for relapsing CD-associated diarrhoea where there is no response to conventional treatment strategies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research